Posted: Wednesday, November 16, 2022
Coffee intake may be linked to longer prostate cancer–specific survival in certain groups, found Justin R. Gregg, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues. According to a multicenter study published in European Urology Oncology, drinking coffee was associated with longer survival among men with a CYP1A2-163AA genotype, a genotype that appears to be associated with a fast caffeine metabolism. According to the study authors, the findings will require further replication and research to determine which patient groups may benefit from consumption of coffee.
The study focused on data on the CYP1A2-163C>A rs762551 single-nucleotide variant associated with caffeine metabolism, coffee intake, and more than 6 months of follow-up from the PRACTICAL Consortium database. This database included 5,727 men with prostate cancer from seven studies conducted in the United States, Australia, and Europe.
Although not statistically significant, higher coffee intake did appear to be associated with longer prostate cancer–specific survival (hazard ratio [HR] = 0.85; 95% confidence interval [CI] = 0.68–1.08; P = .18) and overall survival (HR = 0.90; 95% CI = 0.77–1.07; P = .24). In patients with clinically localized disease, high coffee intake was associated with longer prostate cancer–specific survival (HR = 0.66; 95% CI = 0.44–0.98; P = .040), with comparable results for the group with advanced disease (HR = 0.92; 95% CI = 0.69–1.23; P = .6). However, although high coffee intake was associated with longer survival among men with the CYP1A2-AA genotype (HR = 0.67; 95% CI = 0.49–0.93; P =.017), an association was not found among men with the AC/CC genotype (P = .8), and subgroup analyses found no associations with overall survival.
Disclosures: For full disclosures of study authors, visit euoncology.europeanurology.com.